Publications

Hayes Publications are available through the Hayes Knowledge Center, a portal to world-class research and unbiased analyses on the clinical, financial, and risk impacts of emerging, controversial, and disruptive healthcare technologies.

Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.

See below for some of our recent publications.

Pattern Electroretinography for Diagnosis of Glaucoma

Focus of the Report: This report focuses on pattern electroretinography (PERG) for the diagnosis of glaucoma.

Technology Description: Early diagnosis of glaucoma can reduce the risk of irreversible vision loss and blindness. Electroretinography (ERG) is a minimally invasive procedure that provides an objective assessment of retinal function. PERG is a …

Portable Neuromodulation Stimulator for Gait Deficit due to Multiple Sclerosis

The Portable Neuromodulation Stimulator (PoNS) device is a portable neuromodulation stimulator for short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis for use by prescription only as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older.

Aquablation for Treatment of Benign Prostatic Hyperplasia

Focus of the Report: This report focuses on Aquablation therapy for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH).

Technology Description: Aquablation therapy is a minimally invasive procedure that ablates overgrown prostatic tissue in order to restore patency to the urethral passageway. High-veloci…

Abecma (Idecabtagene Vicleucel) for Multiple Myeloma

Abecma (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Intravenous Ketamine for Chronic Nonmalignant Pain

Focus of the Report: This report focuses on the use of intravenous (IV) ketamine for the treatment of chronic nonmalignant pain.

Technology Description: The hydrochloride (HCl) acid salt of ketamine is a rapid-acting phencyclidine anesthetic indicated for the induction of anesthesia prior to the administration of other general anesthetic agents, as a s…

Evrysdi (Risdiplam) for Spinal Muscular Atrophy

Evrysdi (risdiplam; formerly RG7916) is an oral small molecule splicing modifier of the survival motor neuron 2 (SMN2) gene indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.

Amondys 45 (Casimersen) for Duchenne Muscular Dystrophy

Amondys 45 (casimersen) is an intravenously administered antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.